MRI靶向时代的前列腺活检:趋向审慎使用额外系统活检
回顾性分析745例接受MRI靶向活检联合系统活检的患者,评估仅系统活检额外检出有临床意义前列腺癌的风险。PI-RADS 5、既往活检阴性及较年轻与额外检出风险降低相关;决策曲线分析显示对PI-RADS 5和/或既往活检阴性者免除系统活检可分别避免27%和58%的活检,遗漏有临床意义前列腺癌分别为1%和2%。
要点
- 系统活检额外检出有临床意义前列腺癌47例(6%)。
- PI-RADS 5者仅系统活检检出有临床意义前列腺癌风险低于PI-RADS 3(OR 0.30)和PI-RADS 4(OR 0.33)。
- 对PI-RADS 5和/或既往活检阴性者免除系统活检可减少活检数量而遗漏风险低。
核心结论
- 并非所有男性均同等获益于系统活检联合MRI靶向活检;对PI-RADS 5和/或既往活检阴性者免除系统活检可能减少过度活检且遗漏有临床意义前列腺癌风险低。
研究设计与样本
- 回顾性研究纳入745例接受联合MRI靶向活检加系统活检的患者,以系统活检相对于MRI靶向活检升级检出有临床意义前列腺癌(分级分组≥2)为主要结局,采用逻辑回归识别相关变量并用决策曲线分析评估临床效用。
诊断标准与关键数值
- 系统活检额外检出有临床意义前列腺癌47例(6%)。
- 仅系统活检检出有临床意义前列腺癌的风险:PI-RADS 5 vs PI-RADS 3的OR 0.30(p=0.03),PI-RADS 5 vs PI-RADS 4的OR 0.33(p=0.01)。
- 仅系统活检检出有临床意义前列腺癌的风险:既往活检阴性 vs 既往活检阳性的OR 0.40(p=0.007)。
- 仅系统活检检出有临床意义前列腺癌的风险随年龄增加:每10岁OR 1.64(p=0.016)。
- 决策曲线分析策略:对PI-RADS 5者避免系统活检可避免201例(27%)活检、遗漏有临床意义前列腺癌5例(1%);对PI-RADS 5和既往活检阴性者避免系统活检可避免429例(58%)活检、遗漏有临床意义前列腺癌15例(2%)。
临床应用与阅片要点
- 作者认为对PI-RADS 5和/或既往活检阴性者免除系统活检可能减少过度活检且遗漏有临床意义前列腺癌风险低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: We aimed to develop and compare strategies that help optimize current prostate biopsy practice by identifying patients who may forgo concurrent systematic biopsy (SBx) in favor of MRI-targeted (TBx) alone.
METHODS: Retrospective study on 745 patients who underwent combined MRI-TBx plus SBx. Primary outcome was the upgrade to clinically significant prostate cancer (csPCa; grade group ≥ 2) on SBx versus MRI-TBx. Variables (age, previous biopsy status, Prostate Imaging Reporting and Data System (PI-RADS) score, index lesion size/location, number of lesions, PSA, PSA density, prostate volume) associated with the primary outcome were identified by logistic regression and used for biopsy strategies. Clinical utility was assessed by decision curve analysis (DCA).
RESULTS: SBx detected 47 (6%) additional men with csPCa. The risk of detecting csPCa uniquely on SBx was significantly lower in men with PI-RADS 5 (versus PI-RADS 3: OR 0.30, p = 0.03; versus PI-RADS 4: OR 0.33, p = 0.01), and previous negative biopsy (versus previous positive biopsy: OR 0.40, p = 0.007), and increased with age (per 10 years: OR 1.64, p = 0.016). No significant association was observed for other variables. DCA identified the following strategies as most useful: (a) avoid SBx in men with PI-RADS 5 and (b) additionally in those with previous negative biopsy, resulting in avoiding SBx in 201 (27%) and 429 (58%), while missing csPCa in 5 (1%) and 15 (2%) patients, respectively.
CONCLUSION: Not all men benefit equally from the combination of SBx and MRI-TBx. SBx avoidance in men with PI-RADS 5 and/or previous negative biopsy may reduce the risk of excess biopsies with a low risk of missing csPCa.
KEY POINTS: • In men undergoing MRI-targeted biopsy, the risk of detecting clinically significant prostate cancer (csPCa) only on additional systematic biopsy (SBx) decreased in men with PI-RADS 5, previous negative biopsy, and younger age. • Using these variables may help select men who could avoid the risk of excess SBx. • If missing csPCa in 5% was acceptable, forgoing SBx in men with PI-RADS 5 and/or previous negative biopsy enabled the highest net reduction in SBx.
引用
- Deniffel, Perlis, Ghai, et al. Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy. Eur Radiol. 2022. PMID: 35507051. doi:10.1007/s00330-022-08822-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。